Cochlear Ltd
ASX:COH

Watchlist Manager
Cochlear Ltd Logo
Cochlear Ltd
ASX:COH
Watchlist
Price: 298.23 AUD 1.78% Market Closed
Market Cap: 19.5B AUD
Have any thoughts about
Cochlear Ltd?
Write Note

Cochlear Ltd
Net Issuance of Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Cochlear Ltd
Net Issuance of Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Issuance of Debt CAGR 3Y CAGR 5Y CAGR 10Y
Cochlear Ltd
ASX:COH
Net Issuance of Debt
-AU$32.4m
CAGR 3-Years
57%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
R
Respiri Ltd
ASX:RSH
Net Issuance of Debt
AU$880k
CAGR 3-Years
N/A
CAGR 5-Years
2%
CAGR 10-Years
N/A
ImpediMed Ltd
ASX:IPD
Net Issuance of Debt
-AU$477k
CAGR 3-Years
-26%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
C
Cyclopharm Ltd
ASX:CYC
Net Issuance of Debt
-AU$433.5k
CAGR 3-Years
-15%
CAGR 5-Years
-4%
CAGR 10-Years
12%
Optiscan Imaging Ltd
ASX:OIL
Net Issuance of Debt
-AU$411k
CAGR 3-Years
9%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
EMvision Medical Devices Ltd
ASX:EMV
Net Issuance of Debt
-AU$244.5k
CAGR 3-Years
-36%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Cochlear Ltd
Glance View

Market Cap
19.5B AUD
Industry
Health Care

Cochlear Ltd. is a pioneering Australian company at the forefront of innovative hearing solutions, dedicated to transforming the lives of individuals with hearing loss. Founded in 1981, the company specializes in the development and manufacture of advanced cochlear implants, which are electronic devices that bypass damaged hair cells in the cochlea and stimulate the auditory nerve directly, enabling patients to perceive sound. With a global footprint, Cochlear serves a diverse range of customers, from newborns to adults, and its products are supported by a robust body of clinical evidence and state-of-the-art technology. As a leader in the industry, Cochlear has established strong relationships with healthcare professionals and patients alike, creating a loyal customer base that drives long-term growth. For investors, Cochlear presents a compelling opportunity in the healthcare sector, characterized by its relentless focus on research and development, which ensures a pipeline of innovative products that keep it ahead of competitors. The company’s financial performance has shown resilience, with steady revenue growth and a solid margin due to its unique position in the global market, coupled with a diversified revenue model that includes both product sales and ongoing service agreements. As the global population ages and awareness of hearing loss increases, Cochlear is well positioned to capitalize on the growing demand for its products. With a commitment to sustainability and corporate responsibility, Cochlear not only seeks to enhance shareholder value but also strives to make a meaningful impact on the lives of those with hearing difficulties, aligning its business success with social good.

COH Intrinsic Value
204.64 AUD
Overvaluation 31%
Intrinsic Value
Price

See Also

What is Cochlear Ltd's Net Issuance of Debt?
Net Issuance of Debt
-32.4m AUD

Based on the financial report for Jun 30, 2024, Cochlear Ltd's Net Issuance of Debt amounts to -32.4m AUD.

What is Cochlear Ltd's Net Issuance of Debt growth rate?
Net Issuance of Debt CAGR 3Y
57%

Over the last year, the Net Issuance of Debt growth was 55%. The average annual Net Issuance of Debt growth rates for Cochlear Ltd have been 57% over the past three years .

Back to Top